These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35054865)

  • 1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA.
    Spanakis M; Kontopodis E; Van Cauter S; Sakkalis V; Marias K
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):529-47. PubMed ID: 27647272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
    Shah DK; Balthasar JP
    Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
    Heiskanen T; Heiskanen T; Kairemo K
    Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
    Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
    Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
    Kim H; Folks KD; Guo L; Sellers JC; Fineberg NS; Stockard CR; Grizzle WE; Buchsbaum DJ; Morgan DE; George JF; Zinn KR
    Mol Imaging; 2011 Jun; 10(3):153-67. PubMed ID: 21496446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
    Shah DK; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized time-resolved imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models.
    Haeck J; Bol K; Bison S; van Tiel S; Koelewijn S; de Jong M; Veenland J; Bernsen M
    Contrast Media Mol Imaging; 2015; 10(6):413-20. PubMed ID: 25995102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.
    Kim H; Hartman YE; Zhai G; Chung TK; Korb ML; Beasley TM; Zhou T; Rosenthal EL
    J Magn Reson Imaging; 2015 Oct; 42(4):936-45. PubMed ID: 25704985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
    Polli JR; Engler FA; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
    Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
    MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
    Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
    Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-temporal resolution DCE-MRI improves assessment of intra- and peri-breast lesions categorized as BI-RADS 4.
    Liu Y; Wang S; Qu J; Tang R; Wang C; Xiao F; Pang P; Sun Z; Xu M; Li J
    BMC Med Imaging; 2023 Apr; 23(1):58. PubMed ID: 37076817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.